Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis.
We studied the rate of reactive oxygen species (ROS) production by monocytes 'ex vivo' in a cohort of healthy individuals, in a group of MS patients undergoing treatment with interferon beta-1b and another group of MS patients who refused treatment with interferon beta-1b. The rate of ROS production in healthy individuals was slightly lower than in non-treated MS patients. The lower rate of ROS production was obtained in monocytes of MS patients treated with interferon beta-1b. These results indicate that the treatment of relapsing-remitting MS patients with interferon beta-1b rendered the NADPH oxidase of the monocytes less sensitive to trigger reactive oxygen species (ROS).
Lucas
M
M
Molecular Biology Service of the Virgen Macarena University Hospital, Seville, Spain. Lucas@cica.es
Sánchez-Soliño
O
O
Solano
F
F
Izquierdo
G
G
D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000494:pharmacology* / Q000627:therapeutic use; D007700:Kinetics; D008163:Luminescent Measurements; D008165:Luminol / Q000378:metabolism; D009000:Monocytes / Q000201:enzymology*; D009103:Multiple Sclerosis / Q000097:blood* / Q000628:therapy; D019255:NADPH Oxidases / Q000097:blood*; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000378:metabolism*; D011994:Recombinant Proteins; D012008:Recurrence; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D017382:Reactive Oxygen Species; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D008165:Luminol; D016899:Interferon-beta; D019255:NADPH Oxidases; D013755:Tetradecanoylphorbol Acetate; D000068556:Interferon beta-1a